Change in mean LVMI with erythropoietin alpha hemoglobin maintenance treatment and control/delayed treatment from baseline to 24 months End point Hemoglobin.

Slides:

Advertisements

Similar presentations

When Using DOPPS Slides. DOPPS Slide Use Guidelines.

Advertisements

Solomon Tesfaye et al N Engl J Med 2005;352: Comparison of Baseline Data in 1819 Patients According to Whether There Was an Assessment for Neuropathy.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Selective heart rate reduction with ivabradine unloads the left ventricle in.

Patient disposition Dichtl W, et al. Am J Cardiol. 2008;102:743-8 AVR = aortic valve replacement; MDCT = multidetector computed tomographic.

Baseline Patient Characteristics Bart A.N. Verhoeven, et al. Stroke 2006;37:

1. The STRATA Study. Kidney Transplant 1. The STRATA Study (Study of Transplant-Related Anemia Treated with Aranesp) Source Bloom RD, Bolin P, Gandra.

Baseline Characteristics of 167 Patients Randomly Assigned to Either Placebo or Extended-Release Niacin Allen J. Taylor et al. Circulation 2004; 110:

Switch RPV-TDF-FTC from NVP-Based Regimen NEAR-Rwanda Trial

Epoetin use and Kidney Disease Outcomes Quality Initiative hemoglobin targets in patients returning to dialysis with failed renal transplants C.A. Solid,

Intensive Hemodialysis and Health-related Quality of Life

Locatelli et al. Am J Nephrol 2017;45: (DOI: / )

Intensive Hemodialysis and Health-related Quality of Life

Figure 6 Effects of adiponectin on podocyte function

Figure 2 ALSFRS-R changes (A) Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) slope after 6 months of treatment without (left)

Atorvastatin 20 mg (n=25 lesions) Atorvastatin 5 mg (n=25 lesions)

Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease Martin et al. Am J Nephrol 2017;45: (DOI:

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.

Bakris GL, Burkhart JM, Weinhandl ED, McCullough PA, Kraus MA

Bakris GL, Burkhart JM, Weinhandl ED, McCullough PA, Kraus MA

Nat. Rev. Nephrol. doi: /nrneph

Bushinsky et al. Am J Nephrol 2016;44: (DOI: / )

Red blood cell life span and ‘erythropoietin resistance’

Impact of Cognitive Function Change on Mortality in Renal Transplant and End-Stage Renal Disease Patients Sharma et al. Am J Nephrol 2016;44: (DOI: / )

PREMIER: Rate of hypertension at 18 months

Hammoud et al. Am J Nephrol 2016;44: (DOI: / )

A Six-hour Hemodialysis Without a Significant Increase in Dialysis Dose, as Judged by Kt/V, Can Reduce the Dosage of Erythropoietin Department of Kidney.

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Figure 3 JCV index changes in JCV+ patients

End point Fenoldopam, n (%) Dopamine, n (%) p

CREATE: Baseline values

Response to is the reduction in urea distribution volume over time in clinically stable dialysis patients real? S. Andrulli, S. Di Filippo, F. Locatelli

Volume 64, Issue 5, Pages (November 2003)

Darbepoetin alfa: A new therapeutic agent for renal anemia

This Month in AJKD American Journal of Kidney Diseases

An inflammatory triple negative breast cancer of an African woman before (A) and after (B) treatment. An inflammatory triple negative breast cancer of.

Baseline Characteristics, Values at 24-Month Follow-up, and Changes from Baseline* - Part I John J.P. Kastelein, et al. N Engl J Med 2007;356: online.

Mean (±95%CI) relative delta power at baseline, at the end of treatment and 6 months after the end of treatment in patients with cirrhosis (n=5, black.

Volume 67, Pages S48-S51 (January 2005)

Scatterplot showing the association between change in HbA1c at 1 year and weight change at 1 year, relative to baseline for each treatment group. Scatterplot.

Mean (±95%CI) choice reaction time on the Scan package at baseline, at the end of treatment and 6 months after the end of treatment in patients with cirrhosis.

Recent experience with high-dose intravenous iron administration

DENERHTN Trial design: Patients with resistant hypertension were randomized to renal denervation plus standardized stepped-care antihypertensive treatment.

Francesco Locatelli, Lucia Del Vecchio Kidney International

Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.

Patient Disposition James A. de Lemos et al. JAMA 2004; 292:

(A through C) Mean eGFR during follow-up according to treatment assignment in patients with normoalbuminuria (A), microalbuminuria (B), and macroalbuminuria.

Volume 55, Issue 5, Pages (May 1999)

Epoetin use and Kidney Disease Outcomes Quality Initiative hemoglobin targets in patients returning to dialysis with failed renal transplants C.A. Solid,

Differences in Blood Transfusion Trends Between US and UK Centers

(A) Absolute and (B) change from baseline in 6 min walk distance over time for all patients and by Down syndrome status. (A) Absolute and (B) change from.

Anemia After Renal Transplantation

Universal Sustained Viral Response to the Combination of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with/without Ribavirin in Patients on Hemodialysis.

(A) Absolute and B) change from baseline in 6 min walk distance over time for patients on bosentan monotherapy by Down syndrome status. (A) Absolute and.

The 6MWT results showing improvement from baseline at 1, 6 and 12 months in patients receiving an implant (mean±SE of mean). The 6MWT results showing improvement.

Volume 65, Issue 4, Pages (April 2004)

Age-related prevalence of left ventricular hypertrophy (LVH) in 507 children on CPD using different reference systems. Age-related prevalence of left ventricular.

Mean (SD) weekly hemoglobin level (g/dl) and mean (SD) weekly epoetin dose by body weight (U/kg per week) were similar between epoetin alfa-epbx and epoetin.

Changes to the End-Stage Renal Disease Quality Incentive Program

Baseline characteristics of study population

Mean fasting C-peptide levels (for all subjects [A]) and mean peak C-peptide levels (all subjects [B], adolescents [C], and adults [D])after mixed-meal.

Strategies for iron supplementation: Oral versus intravenous

A loading dose decreases the time to achieve the target concentration.

Changes in glycated hemoglobin (HbA1c) levels after 12 weeks’ treatment with lixisenatide (according to dose increase regimen) or placebo. Changes in glycated.

Mean Pulmonary Artery Pressure Change Post-Thrombectomy Average pre-procedural mean pulmonary artery pressure (mPAP) in patients with pulmonary hypertension.

Mean change in CRT (µm) from baseline to month 12 in patients receiving IVT-AFL. Mean change in CRT (µm) from baseline to month 12 in patients receiving.

Survival, subsequent therapies, and response.

Changes over time of the daily prednisone dose in patients that responded to anakinra. Changes over time of the daily prednisone dose in patients that.

Examples illustrating the study definitions of groups A, B, and C

Per cent change in lumbar spinal bone mineral density (BMD) at 12 months from baseline in all patients (A), patients stratified by baseline use of glucocorticoid.

Distribution of facility mean treatment time, by DOPPS region and phase. Distribution of facility mean treatment time, by DOPPS region and phase. Restricted.

Presentation transcript:

Change in mean LVMI with erythropoietin alpha hemoglobin maintenance treatment and control/delayed treatment from baseline to 24 months End point Hemoglobin maintenance Control/delayed-treatment group Mean change in LVMI (g/m2) 0.37±25.0 5.21±30.3 Levin A et al. Am J Kidney Dis 2005; 46:799-811.

Change in mean LVMI in patients with stable hemoglobin levels and those with decreasing levels End point Stable hemoglobin Decreasing hemoglobin p Change in mean LVMI (g/dL) –0.25±26.7 19.3±28.2 0.002 Levin A et al. Am J Kidney Dis 2005; 46:799-811.